Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.8333.

A number of research firms recently weighed in on SANA. Wedbush raised their target price on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Zacks Research lowered shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright dropped their price objective on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Sana Biotechnology in a report on Monday, December 29th. Finally, Wall Street Zen cut shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of SANA. AQR Capital Management LLC raised its holdings in Sana Biotechnology by 49.8% during the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after buying an additional 190,483 shares during the period. Woodline Partners LP boosted its stake in Sana Biotechnology by 13.1% during the first quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock worth $1,312,000 after buying an additional 90,515 shares during the period. Nisa Investment Advisors LLC increased its position in Sana Biotechnology by 673.8% during the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after acquiring an additional 9,501 shares during the last quarter. Savant Capital LLC bought a new position in Sana Biotechnology during the second quarter valued at $172,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Sana Biotechnology in the second quarter valued at $63,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Trading Down 10.7%

Shares of SANA stock opened at $3.41 on Friday. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $6.55. The stock’s 50-day moving average price is $4.27 and its 200-day moving average price is $4.14. The stock has a market capitalization of $908.31 million, a price-to-earnings ratio of -3.52 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). As a group, research analysts predict that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.